Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: A prospective, randomized, double-masked, placebo-controlled study

Arthritis Research and Therapy

Volumn 13, Issue 4, 2011, Pages

  Plazak, Wojciech ^a   Gryga, Krzysztof ^a   Dziedzic, Hanna ^a   Tomkiewicz Pajak, Lidia ^a   Konieczynska, Malgorzata ^a   Podolec, Piotr ^a   Musial, Jacek ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Accelerated atherosclerosis; Autoimmune disease; MDCT; Perfusion scintigraphy; Scoronary calcification; Statins; Systemic lupus erythematosus

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CALCIUM; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HEART MUSCLE PERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL; CALCINOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DOUBLE BLIND PROCEDURE; HEART; HEART MUSCLE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PROSPECTIVE STUDY; SCINTISCANNING;

ADULT; AGED; CALCINOSIS; CORONARY ARTERY DISEASE; CORONARY VESSELS; DOUBLE-BLIND METHOD; FEMALE; HEART; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; PYRROLES; YOUNG ADULT;

EID: 79960561057     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3402     Document Type: Article

References (44)

1. Bruce IN. "Not only... but also": factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 2005, 44:1492-1502. 10.1093/rheumatology/kei142, 16234277.
2. Lopez-Pedrera C, Aguirre MA, Barbarroja N, Cuadrado MJ. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J Biomed Biotechnol 2010, pii: 607084. 2948929, 20936125 .
3. Pons-Estel GJ, Gonzales LA, Zhang J, Burgos P, Reveille JD, Vila LM, Alarcon GS. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multicenter US cohort. Rheumatology 2009, 48:817-822. 10.1093/rheumatology/kep102, 2722811, 19454606.
4. ALLHAT-LLT Officers and Coordinators Major outcomes in moderately-hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 2002, 288:2998-3007. 10.1001/jama.288.23.2998, 12479764, ALLHAT-LLT Officers and Coordinators.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307. 10.1056/NEJM199511163332001, 7566020.
6. Ray KK, Cannon C, McCabe C, Cairns R, Tonkin A, Sacks F, Jackson G, Braunwald E. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes. J Am Coll Cardiol 2005, 46:1405-1410. 10.1016/j.jacc.2005.03.077, 16226162.
7. Schwartz G, Olsson A, Ezekowitz M, Ganz P, Oliver M, Waters D, Zeiher A, Chaitman B, Leslie S, Stern T. Effect of atorvastatin on early recurrent ischaemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718. 10.1001/jama.285.13.1711, 11277825.
8. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556-1565. 10.1001/jama.295.13.jpc60002, 16533939.
9. Ridker PM, Cannon C, Morrow D, Rifai N, Rose L, McCabe C, Pfeffer M, Braunwald E. C-reactive protein levels and outcomes after statin therapy. New Engl J Med 2005, 352:20-28. 10.1056/NEJMoa042378, 15635109.
10. Masumoto A, Hirooka Y, Hironaga K, Eshima K, Setoguchi S, Egashira K, Takeshita A. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 2001, 88:1291-1294. 10.1016/S0002-9149(01)02090-2, 11728357.
11. Mason JC, Ahmed Z, Mankoff R, Lidington EA, Ahmad S, Bhatia V, Kinderlerer A, Randi AM, Haskard DO. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-induced injury. Circ Res 2002, 91:696-703. 10.1161/01.RES.0000038151.57577.19, 12386146.
12. Giri S, Parke AL, Waters DD. Controlling cardiovascular risk factors in systemic lupus erythematosus. J Musculoskel Med 1998, 15:42-52.
13. Urowitz MB, Gladman DD. How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology (Oxford) 2000, 39:238-244.
14. Samon JE, Roman MJ. Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Curr Opin Rheumatol 2001, 13:341-344. 10.1097/00002281-200109000-00001, 11604586.
15. Noel B. Risks and benefits of statins in lupus erythematosus. Arch Intern Med 2004, 164:107-108. 10.1001/archinte.164.1.107-a, 14718334.
16. Bruce IN. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?. Best Pract Res Clin Rheumatol 2005, 19:823-838. 10.1016/j.berh.2005.05.001, 16150405.
17. Smolen J, Weisman M. Connective tissue disorders. Rheumatology 2008, 1205-1485. Philadelphia, Mosby Elsevier, Hochberg M, Silman A, Smolen J, Weinblatt M, Weisman M.
18. Smith EL, Shmerling RH. The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement. Lupus 1999, 8:586-595. 10.1191/096120399680411317, 10568894.
19. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind study. Lancet 2001, 357:577-581. 10.1016/S0140-6736(00)04053-8, 11558482.
20. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vemalis MN. ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol. A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima media thickness. Circulation 2002, 106:2055-2060. 10.1161/01.CIR.0000034508.55617.65, 12379573.
21. Agatson AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990, 15:827-832. 10.1016/0735-1097(90)90282-T, 2407762.
22. Swadzba J, de Clerck LS, Stevens WJ, Bridts CH, van Cotthem KA, Musial J, Jankowski M, Szczeklik A. Anticardiolipin antibodies, anti-β2-glycoprotein I, antiprothrombin antibodies and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol 1997, 24:1710-1715.
23. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standarisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, 7:1737-1740. 10.1111/j.1538-7836.2009.03555.x, 19624461.
24. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Heamost 2006, 4:295-306.
25. Permarheum SLEDAI Calculator. , http://www.permarheum.org/SLEDAI.html
26. Lin CC, Ding HJ, Chen YW, Wang JJ, Ho ST, Kao A. Usefulness of technetium-99 m sestamibi myocardial perfusion SPECT in detection of cardiovascular involvement in patients with systemic lupus erythematosus or systemic sclerosis. Int J Cardiol 2003, 92:157-161. 10.1016/S0167-5273(03)00106-2, 14659847.
27. Lin JJ, Hsu HB, Sun SS, Wang JJ, Ho ST, Kao CH. Single Photon Emission Computed Tomography of technetium-99 m tetrofosmin myocardial perfusion imaging in patients with systemic lupus erythematosus - a preliminary report. Jpn Heart J 2003, 44:83-89. 10.1536/jhj.44.83, 12622440.
28. Vanzetto G, Ormezzano O, Fagret D, Comet M, Denis B, Machecourt J. Long term additive prognostic value of thalium-201 myocardial perfusion imaging over clinical and exercise stress test in low to intermediate risk patients: study in 1137 patients with 6-year follow-up. Circulation 1999, 100:1521-1527.
29. Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA, Friedman J, Diamond GA. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation 1998, 97:535-543.
30. Yiu KH, Wang S, Mok MY, Ooi GC, Khong PL, Mak KF, Lam KF, Lau CS, Tse HF. Pattern of arterial calcification in patients with systemic lupus erythematosus. J Rheumatol 2009, 36:2212-2217. 10.3899/jrheum.090312, 19755615.
31. Kao AH, Wasko MCM, Krishnaswami S, Wagner J, Edmundowicz D, Shaw P, Cunningham AL, Danchenko N, Sutton-Tyrrell K, Tracy RP, Kuller LH, Manzi S. C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis. Am J Cardiol 2008, 102:755-760. 10.1016/j.amjcard.2008.04.059, 2563802, 18774002.
32. Raggi P, Gongora M, Gopal A, Callister T, Budoff M, Shaw L. Coronary artery calcium to predict all-cause mortality in elderly men and women. J Am Coll Cardiol 2008, 52:17-23. 10.1016/j.jacc.2008.04.004, 18582630.
33. Chang SM, Nabi F, Xu J, Peterson LE, Achari A, Pratt CM, Mahmarian JJ. The coronary artery calcium score and stress myocardial perfusion imaging provide independent and complementary prediction of cardiac risk. J Am Coll Cardiol 2009, 54:1872-1882. 10.1016/j.jacc.2009.05.071, 19892239.
34. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, Greenland P. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010, 303:1610-1616. 10.1001/jama.2010.461, 3033741, 20424251.
35. Uebleis C, Becker A, Griesshammer I, Cumming P, Becker C, Schmidt M, Barterstein P, Hacker M. Stable coronary artery disease: prognostic value of myocardial perfusion SPECT in relation to coronary calcium scoring - long-term follow-up. Radiology 2009, 252:682-690. 10.1148/radiol.2531082137, 19703866.
36. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004, 114:593-595. 10.1016/j.thromres.2004.07.012, 15507296.
37. Petri M, Kiani A, Post W, Christopher-Stine L, Madger L. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011, 70:760-765. 10.1136/ard.2010.136762, 21177297.
38. Bannwarth B, Miremont G, Papapietro PM. Lupuslike syndrome associated with simvastatin. Arch Intern Med 1992, 152:1093.
39. Hanson J, Bossingham D. Lupus-like syndrome associated with simvastatin. Lancet 1998, 352:1070.
40. Srivastana M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R, Ha E, Anhalt GJ, Provost TT, Nousari CH. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 2003, 139:45-49. 10.1001/archderm.139.1.45, 12533163.
41. Noel B. Statins and lupus erythematosus. Rheumatology 2004, 43:397-398.
42. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nature Med 2000, 6:1399-1400. 10.1038/82219, 11100127.
43. Long BR, Leya F. The role of antiphospholipid syndrome in cardiovascular disease. Hematol Oncol Clin N Am 2008, 22:79-94.
44. Alexanderson E, Gomez-Leon A, Vargas A, Romero JL, Sierra Fernandez C, Rodriguez Valero M, Garcia Rojas L, Meave A, Amigo MC. Myocardial ischaemia in patients with primary APS: a 13N-ammonia PET assessment. Rheumatology 2008, 47:894-896. 10.1093/rheumatology/ken084, 18403401.